Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

PipISB

CB1 inverse agonist (Kb 1.5 nM) evaluated as a PET radiotracer in monkeys in 2009.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₇H₂₆FN₃O₃S

CID 58975213

Family
ECS pharmacological toolAntagonist or inverse agonist
Molar mass
491.60 g/mol

Updated on

In plain terms

PipISB is not a medicine but a tracer: made radioactive, it can be used to visualise CB1 receptors in the living brain by positron emission tomography. In 2009, it was tested in monkeys, where it attached in regions rich in CB1 receptors. No use in humans was found in the sources consulted.

Receptors and activity

Target network

CB1Inverse agonistinverse agonist; functional antagonism constant Kb = 1.5 nM (value recalled in the introduction of Finnema et al. 2009, from earlier work)
  • Blocks or inhibits
  • Binds or modulates

The lower the cited value, the closer the target sits to PipISB: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of PipISB.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1Inverse agonistno measured value cited

    inverse agonist; functional antagonism constant Kb = 1.5 nM (value recalled in the introduction of Finnema et al. 2009, from earlier work)

  2. CB2Binding (function not established)no measured value cited

    Kb greater than 7 000 nM (Finnema et al. 2009, same source): no useful affinity

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

PipISB is an inverse agonist of the CB1 receptor designed as a radioligand: the aim is to measure, not to treat. Finnema and colleagues (2009) recall that it combines high potency (Kb of 1.5 nM at CB1) with high selectivity over CB2 (Kb above 7,000 nM), and that it can be labelled either with carbon-11, of short half-life, or with fluorine-18. In monkeys, brain uptake was highest in the striatum and cerebellum, reaching 170 to 270 % standardised uptake value (SUV) 120 minutes after injection of [11C]PipISB and 180 % 240 minutes after that of [18F]PipISB, with good retention in all CB1-rich regions; after pretreatment with a receptor-saturating dose of a CB1 ligand, values fell to 70-80 % SUV at 120 minutes for [11C]PipISB and to 25 % SUV at 240 minutes for [18F]PipISB. No reference region free of binding could be identified. The authors conclude that both radioligands show high CB1-specific binding in monkey brain in vivo and merit further investigation as PET radioligands in humans (Finnema et al. 2009). No human data were found in the sources consulted.

History

Source
Entirely synthetic compound with no known natural occurrence. It was prepared as a candidate radiotracer for positron emission tomography; no therapeutic use was found in the sources consulted.

Origin

Research tool

No known biosynthetic pathway: a synthetic molecule. It is an N-sulfonylated indole bearing a piperidine at position 3, linked through the sulfonyl group to an N-(4-fluorobenzyl)benzamide; carbon-11 is introduced on the amide carbonyl and fluorine-18 on the fluorobenzyl group (Finnema et al. 2009).

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Antagonist or inverse agonist

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

PipISB (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

IUPAC name
N-[(4-fluorophenyl)methyl]-4-(3-piperidin-1-ylindol-1-yl)sulfonylbenzamide
Other names
[11C]PipISB · [18F]PipISB

Identifiers

Formula
C₂₇H₂₆FN₃O₃S
InChIKey
RXTQWWFLLRSBCM-UHFFFAOYSA-N
SMILES
C1CCN(CC1)C2=CN(C3=CC=CC=C32)S(=O)(=O)C4=CC=C(C=C4)C(=O)NCC5=CC=C(C=C5)F

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.